BMS-564929

ID: bms564929

Aliases: BMS-564,929, PS178990

Type: compound

Route/form: oral or route depends on studied product

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: preclinical, review

Linked sources: 2

Broad outcomes: Muscle growth / performance / recovery, PEDs / AAS / thermogenics

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• androgen receptor modulator
• nonsteroidal SARM

Optimization domains

• SARM
• muscle
• bone
• androgen therapy

Research basis

• Preclinical work describes potent oral anabolic activity with reduced prostate stimulation compared with classic androgen exposure.
• It is a useful literature anchor for the original therapeutic promise of SARMs and why tissue-selective AR agonism became attractive.
• The class review notes high myoanabolic potency but also a narrow therapeutic-index concern around LH suppression.

Limits, risks, and missing evidence

• Preclinical selectivity does not equal safe human performance use.
• LH/HPG-axis suppression and narrow therapeutic-index concerns appear in class reviews.
• No mature healthy-human performance or long-term safety evidence was identified.

Risk flags

• research compound
• preclinical only
• sarm class risk
• endocrine suppression possible
• doping

Linked papers, labels, and reviews

1. An orally active SARM is efficacious on bone, muscle, and sex function with reduced impact on prostate
   preclinical / pubmed_bms564929_preclinical_2006
   Preclinical tissue-selectivity work for orally active nonsteroidal SARMs including the BMS lineage.
2. Selective androgen receptor modulators in preclinical and clinical development
   review / pubmed_sarms_preclinical_clinical_2009
   SARM class review covering multiple preclinical and early clinical programs.